ORAGENICS INC (OGEN)
AMEXHealth CareBiotechnologySnapshot 2026-09-09
$0.52-1.40%
Close 2026-09-09 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Maintain operating losses near -$2.2M net income and cash flow: metric not reported.
Oragenics advances its lead drug ONP-002 with Phase IIa trials approved. The company appointed John Spencer as CFO to strengthen financial leadership. Management aims to control operating losses near -$2.2M net income and cash flow in 2026-Q1. These steps support potential future value from its antibiotic pipeline.
Oragenics remains loss-making with negative cash flow of -$2.2M in 2026-Q1. There is no revenue or EPS growth expected in 2026, with consensus EPS at -$0.69. The company faces high risk and a weak financial position with no clear path to profitability.
The market prices Oragenics near our fair value of $1.48 with implied negative growth of -27% over 3 years. This reflects skepticism about near-term earnings and revenue, which aligns with consensus EPS of -$0.69 in 2026. Our view differs by focusing on pipeline progress and leadership changes as potential catalysts.
Breaks if: significant delays or failure in Phase IIa trial progress
Breaks if: net income or cash from operations falls below -$2.2M per quarter persistently
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces high risks, but it operates in a sector with favorable momentum.
The market appears to have low expectations for OGEN, given its loss-making status and the current valuation premium compared to peers. There is a divergence in expectations, with the company priced at a premium despite its challenges.
Management is focused on advancing clinical development for ONP-002 and building a new therapeutic platform. However, the recent legal and regulatory issues may pose risks to its financial performance in the near term.
The thesis hinges on the company's ability to navigate regulatory challenges and successfully advance its clinical trials. Additionally, broader sector performance and economic indicators will be critical in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: no measurable improvement in financial management or cost control
In the next 1 to 3 years, OGEN's outlook is uncertain due to high risks and recent setbacks. Not investment advice.